A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Intralipid 20% Administered Weekly in Subjects With Advanced Malignant Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2008
At a glance
- Drugs Simotaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Wyeth; Wyeth Pharmaceuticals
- 11 Nov 2008 Checked against NYU Medical Center site.
- 09 Dec 2006 Status change
- 17 Aug 2005 New trial record.